In the distant, non-injected tumor, the combination increased CD8+ T-cell activation (defined as CD69+, Ki67+, or ICOS+) as early as one day after treatment, and T-cell infiltration was increased one week after treatment. The gene discussed is CD8A; the disease is neoplasm.